GSK’s CEO Is Hunting for Acquisitions to Keep Up Momentum

GSK Plc Chief Executive Officer Emma Walmsley is looking for acquisitions in the drugmaker’s core business areas to keep up the “tremendous momentum” she sees heading into 2024.

Walmsley said Monday that she’s watching for deals that would expand the UK company’s existing pipeline in vaccines, specialty medicines, infectious diseases, respiratory drugs and oncology. The company is pursuing a number of development areas as it prepares for the loss of exclusivity on some of its best-selling drugs, including a key HIV treatment later this decade.

“I feel really good on the progress we are making for the chapter beyond that ...